Novo Nordisk CEO Is 'Quite Optimistic' About 2018 Growth

The transcript covers various business aspects of Novo Nordisk, including concerns about patent cliffs and currency risks, the company's optimistic outlook for 2018, and the impact of US tax reforms. It discusses the momentum in the diabetes market, product launches, and the challenges of drug pricing in the US. The conversation also touches on M&A activities, highlighting the company's disciplined approach to acquisitions and partnerships.

How does the company view its competitive position in the diabetes market?

What factors are contributing to the pricing dynamics of insulin in the US market?

What are the company's plans regarding mergers and acquisitions in the biopharma space?